(4S)-3-ethyl-2-oxo-1-propylimidazolidine-4-carboxylic acid | 845546-49-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4S)-3-ethyl-2-oxo-1-propylimidazolidine-4-carboxylic acid
• CAS: 845546-49-8
• 化学式: C₉H₁₆N₂O₃
• 分子量: 200.238
• InChiKey: UMILUSLKEKMPJZ-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  60.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4S)-3-ethyl-2-oxo-1-propylimidazolidine-4-carboxylic acid 、 tert-butyl (2S)-2-[(1S,2S)-2-amino-3-(3,5-difluorophenyl)-1-hydroxypropyl]-4-benzyl-3-oxopiperazine-1-carboxylate 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 生成
  参考文献：
  名称：

  Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors

  摘要：

  Guided by structure-based design, we synthesized two novel series of potent inhibitors of BACE1 and generated extensive SAR around both the prime and non-prime side binding pockets. The key feature of both series is a cyclic amine motif specifically crafted to achieve interactions with both the flap and with the S2' pocket.

  DOI：

  10.1016/j.bmcl.2008.04.050
• 作为产物：
  描述：

  (4S)-2-oxo-1-propylimidazolidine-4-carboxylic acid 、 alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydride 作用下， 生成 (4S)-3-ethyl-2-oxo-1-propylimidazolidine-4-carboxylic acid
  参考文献：
  名称：

  Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors

  摘要：

  Guided by structure-based design, we synthesized two novel series of potent inhibitors of BACE1 and generated extensive SAR around both the prime and non-prime side binding pockets. The key feature of both series is a cyclic amine motif specifically crafted to achieve interactions with both the flap and with the S2' pocket.

  DOI：

  10.1016/j.bmcl.2008.04.050

文献信息

• CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT
  申请人：Cumming Jared N.

  公开号：US20090312341A1

  公开（公告）日：2009-12-17

  Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is X is —O—, —C(R 14 ) 2 — or —N(R)—; Z is —C(R 14 ) 2 — or —N(R)—; t is 0, 1, 2 or 3; each R and R 2 is independently H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl or alkynyl; each R 14 is H, alkyl, alkenyl, alkynyl, halo, —CN, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, —OR 35 , —N(R 24 ) (R 25 ) or —SR 35 ; R 41 is alkyl, cycloalkyl, —SO 2 (alkyl), —C(O)-alkyl, —C(O)-cycloalkyl or -alkyl-NH—C(O)CH 3 ; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula I. Also disclosed are pharmaceutical compositions and methods of treatment comprising compounds of formula I in combination with other agents useful in treating cognitive or neurodegenerative diseases.

  本发明涉及公式I的新化合物或其药学上可接受的盐或溶剂，其中R1为X为—O—，—C（R14）2—或—N（R）—；Z为—C（R14）2—或—N（R）—；t为0、1、2或3；每个R和R2独立地为H，烷基，环烷基，环烷基烷基，芳基，杂芳基，杂环烷基，芳基烷基，杂芳基烷基，杂环烷基烷基，烯基或炔基；每个R14为H，烷基，烯基，炔基，卤素，—CN，卤代烷基，环烷基，环烷基烷基，芳基，杂芳基，杂环烷基，芳基烷基，杂芳基烷基，杂环烷基烷基，—OR35，—N（R24）（R25）或—SR35；R41为烷基，环烷基，—SO2（烷基），—C（O）-烷基，—C（O）-环烷基或-烷基-NH-C（O）CH3；其余变量如规范中所定义。本发明还涉及包含公式I化合物的制药组合物以及使用公式I化合物治疗认知或神经退行性疾病的方法。本发明还涉及包含公式I化合物的制药组合物和治疗方法，其中该组合物与其他对治疗认知或神经退行性疾病有用的药物一起使用。
• US7598250B2
  申请人：——

  公开号：US7598250B2

  公开（公告）日：2009-10-06
• US7910590B2
  申请人：——

  公开号：US7910590B2

  公开（公告）日：2011-03-22
• Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors
  作者：J.N. Cumming、T.X. Le、S. Babu、C. Carroll、X. Chen、L. Favreau、P. Gaspari、T. Guo、D.W. Hobbs、Y. Huang、U. Iserloh、M.E. Kennedy、R. Kuvelkar、G. Li、J. Lowrie、N.A. McHugh、L. Ozgur、J. Pan、E.M. Parker、K. Saionz、A.W. Stamford、C. Strickland、D. Tadesse、J. Voigt、L. Wang、Y. Wu、L. Zhang、Q. Zhang

  DOI：10.1016/j.bmcl.2008.04.050

  日期：2008.6

  Guided by structure-based design, we synthesized two novel series of potent inhibitors of BACE1 and generated extensive SAR around both the prime and non-prime side binding pockets. The key feature of both series is a cyclic amine motif specifically crafted to achieve interactions with both the flap and with the S2' pocket.